Merck buys Australia’s Viralytics
Merck & Co is broadening its immuno-oncology offering through the purchase of Australian group Viralytics in a deal worth $394 million.
Read More
Tag: oncolytic immunotherapy
- MHRA approves new treatment for severe alopecia areata
- Aplagon doses first patient in phase 2a trial of APAC
- NHS to offer fezolinetant for menopause‑related hot flushes and night‑sweats
- UCB reports superiority of bimekizumab in psoriatic arthritis study
- Kainova reports positive results for DT‑9081 in advanced solid tumours
